Goldschmidt R H, Moy A
San Francisco General Hospital, California, USA.
Am Fam Physician. 1996 Aug;54(2):574-80, 587-8.
As new antiretroviral drugs for the treatment of human immunodeficiency virus (HIV) infection and new tests to measure HIV infection have become available, primary care clinicians now have more management options than ever before. Viral load measurements are becoming more accepted as a means of assessing HIV disease and estimating the efficacy of specific drug regimens. Clinical status changes also mark times to review antiretroviral regimens. Potential benefits of combination drug therapy, including the new protease inhibitor class of drugs, have added a new sense of optimism to the care of patients with HIV. Whether combination therapy and protease inhibitor treatment will live up to their promise by inducing better long-term clinical results remains to be seen.
随着用于治疗人类免疫缺陷病毒（HIV）感染的新型抗逆转录病毒药物以及检测HIV感染的新测试方法的出现，基层医疗临床医生现在拥有了比以往任何时候都更多的管理选择。病毒载量检测作为评估HIV疾病和估计特定药物治疗方案疗效的一种手段，越来越被人们所接受。临床状况的变化也是审查抗逆转录病毒治疗方案的时机。联合药物治疗的潜在益处，包括新型蛋白酶抑制剂类药物，为HIV患者的护理增添了新的乐观情绪。联合治疗和蛋白酶抑制剂治疗是否能通过产生更好的长期临床效果来兑现其承诺，还有待观察。
